In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN program priorities

This article was originally published in The Rose Sheet

Executive Summary

FDA issues request for input on Center for Food Safety and Applied Nutrition's 2003 program priorities in June 21 Federal Register notice. Comments must be submitted to FDA by August 20, agency says. CFSAN's program work plan, which will run from Oct. 1 until Sept. 30, 2003, will be available in the fall, according to FDA. Agency anticipates initiatives in 2003 will be aimed at increasing security of U.S. food supply and notes "progress will continue towards development of a centralized adverse event reporting system"...

You may also be interested in...



CFSAN Colour Index Nomenclature Acceptance Tops CTFA Priority Request

FDA should permit the use of the European-developed Colour Index nomenclature for color additive labeling in place of existing agency requirements, according to the Cosmetic, Toiletry and Fragrance Association

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel